Medtronic has launched a clinical trial to evaluate the feasibility of using spinal cord stimulation (SCS) to improve the clinical signs and symptoms of heart failure.
Heart failure stimulates the sympathetic nervous system, resulting in progression of the disease.
The study will evaluate if SCS can restore the natural balance between the sympathetic and parasympathetic nervous systems to restore heart function.
The procedure uses a neurostimulator, connected to the spinal cord with a thin wire or lead, to deliver low-intensity electrical pulses.
During the trial, patients will be implanted with a neurostimulator that delivers stimulation for 12 hours a day.
The randomised feasibility trial will include NYHA Class III systolic heart failure patients at 15 centres across the world, who will then be followed for a period of 12 months.